BridgeMD
Phase 2a, double-blind, randomized, placebo-controlled trial of methylprednisolone versus placebo in patients with cognitive deficits in post-COVID-19 syndrome (PCS) - PoCoVIT
EU CTIS ID: 2023-504826-21-00
What this study is testing
Improvement in memory satisfaction from baseline to week 8 when comparing methyl-prednisolone with placebo in PCS patients
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- History of confirmed (PCR or serology or rapid antigen detection and sick note or comparable certificate after Dec 21, 2023) SARS-CoV-2 infection according to WHO criteria
- Ongoing symptoms of PCS for ≥ 3 months
- Self-reported cognitive deficits at screening
You likely can't join if
- Any ongoing central nervous system disease
- Any major psychiatric disease within the last 10 years
- Previous medical history of gastric ulcer, osteoporosis and/or previous vertebral fractures, rheumatological disease or metabolic disease including diabetes mellitus
- Ongoing immunosuppressive therapy
- Patient is pregnant or breastfeeding at screening
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.